Suppr超能文献

使用Gelucire 50/13对无定形药物进行稳定化处理的机制研究。

Study on mechanism for amorphous drug stabilization using gelucire 50/13.

作者信息

Shimpi Shamkant Laxman, Mahadik Kakasaheb Ramoo, Paradkar Anant Raghunath

机构信息

Formulation Research Division, APL Research Centre, Aurobindo Pharma Ltd, India.

出版信息

Chem Pharm Bull (Tokyo). 2009 Sep;57(9):937-42. doi: 10.1248/cpb.57.937.

Abstract

Methods of preparation and application of amorphous form are well established but it is equally important to note that devitrification of amorphous drugs has limited their applications. Present study was performed to investigate mechanism for amorphous drug stabilization using Gelucire in comparison with polyvinylpyrrolidone (PVP). Etoricoxib and celecoxib were taken as model drugs for this study, as etoricoxib has only proton accepting site for hydrogen bonding in comparison with celecoxib, which has both proton accepting and donating site. Solid dispersion of celecoxib with polyvinylpyrrolidone and Gelucire was prepared by spray drying and melt-granulation technique respectively. X-ray powder diffractometry and differential scanning calorimetry were used to study the physical state of the drug. Dissolution studies were performed to differentiate dissolution performance. Stability study samples were evaluated for physical state of the drug and dissolution performance. An IR study in correlation with molecular modeling was carried out to study the mechanism for stabilization. Dissolution of melt-granulation of amorphous celecoxib was improved significantly as compared to amorphous celecoxib and Celecoxib-PVP solid dispersion. Melt-granulation with lipid seemed to be more dominant than amorphization of drug for improving dissolution. Stability data revealed that PVP was significantly advantageous for amorphous form stabilization whereas Gelucire failed in case of Celecoxib. In contrast to this, our previous study revealed the stabilization ability of Gelucire for amorphous etoricoxib. Molecular modeling and IR studies revealed that H-bonding was predominant mechanism for stabilization. Out of two proposed mechanism for amorphous drug stabilization by lipids, H-bonding ability is more dominant than immobilization of molecule in lipid matrix.

摘要

非晶态形式的制备和应用方法已经成熟,但同样重要的是要注意到非晶态药物的析晶限制了它们的应用。本研究旨在探讨与聚乙烯吡咯烷酮(PVP)相比,使用Gelucire来稳定非晶态药物的机制。本研究选用依托考昔和塞来昔布作为模型药物,因为与塞来昔布具有质子接受和供体位点相比,依托考昔只有质子接受位点用于氢键形成。塞来昔布与聚乙烯吡咯烷酮和Gelucire的固体分散体分别通过喷雾干燥和熔融造粒技术制备。采用X射线粉末衍射法和差示扫描量热法研究药物的物理状态。进行溶出度研究以区分溶出性能。对稳定性研究样品的药物物理状态和溶出性能进行评估。开展了与分子模拟相关的红外研究以探讨稳定化机制。与非晶态塞来昔布和塞来昔布-PVP固体分散体相比,非晶态塞来昔布熔融造粒的溶出度显著提高。对于改善溶出度,脂质熔融造粒似乎比药物非晶化更具优势。稳定性数据表明,PVP对非晶态形式的稳定化具有显著优势,而在塞来昔布的情况下Gelucire则无效。与此相反,我们之前的研究揭示了Gelucire对非晶态依托考昔的稳定化能力。分子模拟和红外研究表明,氢键是稳定化的主要机制。在脂质稳定非晶态药物的两种提出的机制中,氢键能力比分子固定在脂质基质中更具优势。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验